JP2012025766A5 - - Google Patents

Download PDF

Info

Publication number
JP2012025766A5
JP2012025766A5 JP2011210306A JP2011210306A JP2012025766A5 JP 2012025766 A5 JP2012025766 A5 JP 2012025766A5 JP 2011210306 A JP2011210306 A JP 2011210306A JP 2011210306 A JP2011210306 A JP 2011210306A JP 2012025766 A5 JP2012025766 A5 JP 2012025766A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
extracellular domain
extracellular
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011210306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012025766A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012025766A publication Critical patent/JP2012025766A/ja
Publication of JP2012025766A5 publication Critical patent/JP2012025766A5/ja
Pending legal-status Critical Current

Links

JP2011210306A 1999-12-23 2011-09-27 炎症を治療するための方法 Pending JP2012025766A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47089899A 1999-12-23 1999-12-23
US09/470,898 1999-12-23
US21334100P 2000-06-22 2000-06-22
US60/213,341 2000-06-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011133929A Division JP2012025737A (ja) 1999-12-23 2011-06-16 炎症を治療するための方法

Publications (2)

Publication Number Publication Date
JP2012025766A JP2012025766A (ja) 2012-02-09
JP2012025766A5 true JP2012025766A5 (enExample) 2014-04-03

Family

ID=26907985

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001547170A Withdrawn JP2003535037A (ja) 1999-12-23 2000-12-22 炎症を治療する方法
JP2011133929A Pending JP2012025737A (ja) 1999-12-23 2011-06-16 炎症を治療するための方法
JP2011210306A Pending JP2012025766A (ja) 1999-12-23 2011-09-27 炎症を治療するための方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2001547170A Withdrawn JP2003535037A (ja) 1999-12-23 2000-12-22 炎症を治療する方法
JP2011133929A Pending JP2012025737A (ja) 1999-12-23 2011-06-16 炎症を治療するための方法

Country Status (10)

Country Link
EP (6) EP1244708B8 (enExample)
JP (3) JP2003535037A (enExample)
AT (2) ATE459369T1 (enExample)
AU (1) AU2458001A (enExample)
CA (1) CA2395406C (enExample)
DE (2) DE60043957D1 (enExample)
DK (1) DK1616575T3 (enExample)
ES (1) ES2387394T3 (enExample)
PT (1) PT1616575E (enExample)
WO (1) WO2001046261A1 (enExample)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739420B2 (en) * 1997-11-26 2001-10-11 Zymogenetics Inc. Mammalian cytokine-like polypeptide-10
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7189400B2 (en) 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7122632B2 (en) 1999-12-23 2006-10-17 Zymogenetics, Inc. Soluble Interleukin-20 receptor
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
WO2001046261A1 (en) * 1999-12-23 2001-06-28 Zymogenetics, Inc. Method for treating inflammation
DK1246846T3 (da) 1999-12-23 2008-12-08 Zymogenetics Inc Oplöselig interleukin-20-receptor
US20030023033A1 (en) * 2001-07-26 2003-01-30 Laure Dumoutier Novel class II cytokine receptors and uses thereof
EP2177616B1 (en) 2000-08-08 2012-02-29 ZymoGenetics, Inc. Soluble zcytor 11 cytokine receptors
WO2002022153A2 (en) * 2000-09-15 2002-03-21 Zymogenetics, Inc. Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
EP1992643A3 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1432431B1 (en) * 2001-10-04 2017-05-10 Genetics Institute LLC Methods and compositions for modulating interleukin-21 activity
AU2002357283B2 (en) 2001-12-17 2007-08-16 Zymogenetics, Inc. Method for treating cervical cancer
EP1498137A1 (en) * 2002-04-25 2005-01-19 Chugai Seiyaku Kabushiki Kaisha Remedy for lung cancer
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
AU2004223837C1 (en) * 2003-03-24 2012-03-15 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP1653995A1 (en) 2003-08-08 2006-05-10 Novo Nordisk A/S Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
WO2005052000A2 (en) 2003-11-21 2005-06-09 Zymogenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
MX2010013565A (es) * 2008-06-30 2011-01-14 Novo Nordisk As Anticuerpos de interleucina-20 anti-humanos.
CA2739794A1 (en) * 2008-10-07 2010-04-15 National Cheng Kung University Use of il-20 antagonists for treating rheumatoid arthritis and osteoporosis
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
JP2013514795A (ja) 2009-12-22 2013-05-02 ノバルティス アーゲー 治療における使用のための四価cd47抗体定常領域融合タンパク質
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
ES2544608T3 (es) 2010-11-17 2015-09-02 Genentech, Inc. Conjugados de anticuerpo y de alaninil-maitansinol
MX2013013054A (es) 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
US20140193408A1 (en) 2011-06-16 2014-07-10 Novartis Ag Soluble proteins for use as therapeutics
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
UY34346A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
WO2013055987A1 (en) 2011-10-14 2013-04-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
EP2812445A2 (en) 2012-02-10 2014-12-17 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
PL2906251T3 (pl) 2012-10-12 2018-02-28 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22
MX364328B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
HRP20181646T2 (hr) 2012-10-12 2019-08-09 Adc Therapeutics Sa Konjugati pirolobenzodiazepin - anti-psma protutijela
WO2014057117A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014140862A2 (en) 2013-03-13 2014-09-18 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP2968585B1 (en) 2013-03-13 2018-07-18 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6445519B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピン及びそのコンジュゲート
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
JP6895254B2 (ja) 2013-12-16 2021-06-30 ジェネンテック, インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
CA2928952A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
JP6449338B2 (ja) 2014-06-06 2019-01-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company グルココルチコイド誘導腫瘍壊死因子受容体(gitr)に対する抗体およびその使用
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10077318B2 (en) 2014-09-12 2018-09-18 Genentech, Inc. Cysteine engineered antibodies and conjugates
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック, インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
LT3221346T (lt) 2014-11-21 2020-11-10 Bristol-Myers Squibb Company Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
JP6812364B2 (ja) 2015-06-03 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 癌診断用抗gitr抗体
NZ741261A (en) 2015-10-02 2019-11-29 Genentech Inc Pyrrolobenzodiazepine antibody drug conjugates and methods of use
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
EP3365025B1 (en) 2015-10-20 2020-07-15 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
CN108738324B (zh) 2015-11-19 2022-06-21 百时美施贵宝公司 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3433621A1 (en) 2016-03-25 2019-01-30 H. Hoffnabb-La Roche Ag Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
UA125198C2 (uk) 2017-02-08 2022-01-26 Ейдісі Терапьютікс Са Кон'югати піролобензодіазепін-антитіло
SI3612537T1 (sl) 2017-04-18 2022-10-28 Medimmune Limited Konjugati pirolobenzodiazepina
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
KR20200006115A (ko) 2017-05-16 2020-01-17 브리스톨-마이어스 스큅 컴퍼니 항-gitr 효능제 항체에 의한 암의 치료
JP7145891B2 (ja) 2017-06-14 2022-10-03 アーデーセー セラピューティクス ソシエテ アノニム 抗cd19 adcを投与するための投与レジメ
BR112020003003A2 (pt) 2017-08-18 2020-08-11 Medimmune Limited conjugados de pirrolobenzodiazepina
AU2018337815A1 (en) 2017-09-20 2020-03-12 Ph Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
EP4051313A4 (en) * 2019-10-28 2024-04-24 LBL Biotechnology Inc. Treating tissue fibrosis and/or injury and-or organ failure with interleukin 24 or interleukin 20 antagonist
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
JP2026502860A (ja) 2022-12-23 2026-01-27 ジェネンテック, インコーポレイテッド セレブロン分解剤コンジュゲートおよびその使用
CN121263210A (zh) 2023-04-17 2026-01-02 沛科生物公司 抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
PT873405E (pt) 1996-01-11 2005-01-31 Immunex Corp Elementos de sequencia que aumentam a expressao (ease) para sistemas de expressao eucarioticos
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US6486301B1 (en) * 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
WO1999003982A1 (en) * 1997-07-16 1999-01-28 Human Genome Sciences, Inc. Interleukin-20
AU739420B2 (en) * 1997-11-26 2001-10-11 Zymogenetics Inc. Mammalian cytokine-like polypeptide-10
EP1062332A2 (en) 1998-03-09 2000-12-27 Schering Corporation Human receptor proteins; related reagents and methods
AU4411699A (en) * 1998-06-05 1999-12-20 Human Genome Sciences, Inc. Interferon receptor hkaef92
EP1141008A1 (en) * 1998-12-31 2001-10-10 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
DK1246846T3 (da) * 1999-12-23 2008-12-08 Zymogenetics Inc Oplöselig interleukin-20-receptor
WO2001046261A1 (en) * 1999-12-23 2001-06-28 Zymogenetics, Inc. Method for treating inflammation

Similar Documents

Publication Publication Date Title
JP2012025737A5 (enExample)
JP2012025766A5 (enExample)
JP2015530983A5 (enExample)
JP7138046B2 (ja) 二特異性抗体基幹
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
JP2018033454A5 (enExample)
RU2021134101A (ru) Модифицированная j-цепь
RU2015129640A (ru) Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
CN112839955A (zh) 经工程改造双特异性蛋白
JP2017529067A5 (enExample)
JP2019500862A5 (enExample)
MX2020011391A (es) Anticuerpo bcma humanizado y linfocitos t car-bcma.
JP2016511277A5 (enExample)
FI3665192T3 (fi) Muunneltuja transferriinireseptoria sitovia polypeptidejä
NZ618129A (en) Compositions of humanized notch fusion proteins and methods of treatment
EA200870555A1 (ru) Слитые белки, их применение и способы их получения
WO2009007244A3 (en) Replication deficient influenza virus for the expression of heterologous sequences
JP2014158485A5 (enExample)
JP2014503198A5 (enExample)
RU2015142999A (ru) Слитые белки, содержащие связывающие части pdgf и vegf, и способы их применения
PE20140772A1 (es) Polipeptidos que se enlazan a cxcr2
RU2013140472A (ru) Слитый белок антиангиогенного индуцирующего фактора и его применение
NZ602905A (en) Fgf-r4 receptor-specific antagonists
HRP20161656T4 (hr) Sredstva za vezanje na cd33
JP2018530331A5 (enExample)